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Abstract
Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared
findings with recent trials of pharmacological inhibitors of PCSK9.
Methods: Published and individual participant level data (300,000+ participants) were combined to construct a weighted
PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing
data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration.
Results: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in
direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42;
0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57;
1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were
1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials.
No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease,
or Alzheimer’s disease – outcomes for which large-scale trial data were unavailable.
Conclusions: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major
blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown;
although precision was moderate.
Keywords: Genetic association studies, Mendelian randomisation, LDL-cholesterol, Phenome-wide association scan
Background
Statins and ezetimibe reduce the risk of major coronary
events and ischemic stroke via lowering of low density
lipoprotein-cholesterol (LDL-C) [1–3]. Loss-of-function
mutations in PCSK9 are associated with lower LDL-C and
a reduced risk of coronary heart disease (CHD) [4, 5].
Antibodies (mAbs) inhibiting PCSK9, reduce LDL-C in
patients with hypercholesterolaemia, and received market
access in 2015. The FOURIER and ODYSSEY OUT-
COMES trials tested the efficacy of PCSK9-inhibition
versus placebo on the background of statin treatment and
both found that PCSK9 inhibition led to a 15% relative
risk reduction of major vascular events in patients with
established CVD and recent acute coronary syndrome
over a median follow up of 2.2 to 2.8 years [6, 7].
Evidence is limited on the effect of PCSK9 inhibition on
clinical outcomes, and on safety outcomes that might only
become apparent with prolonged use. Nor is evidence
available on the efficacy and safety of PCSK9 inhibitors in
subjects other than the high-risk patients studied in trials.
Mendelian randomisation for target validation uses
naturally-occurring variation in a gene encoding a drug
target to identify mechanism-based consequences of
pharmacological modification of the same target [8]. Such
studies have previously proved useful in predicting success
and failure in clinical trials and have assisted in delineating
on-target from off-target actions of first-in-class drugs [9–
13]. For example, previous studies showed that variants in
HMGCR, encoding the target for statins, were associated
with lower concentrations of LDL-C and lower risk of cor-
onary heart disease [9] (CHD), while confirming the on-
target nature of the effect of statins on higher body weight
and higher risk of type 2 diabetes (T2DM) [9].
We characterised the phenotypic consequences of
genetic variation at PCSK9 in a large, general popula-
tion sample focussing on therapeutically relevant bio-
markers, cardiovascular disease (CVD), individual CVD
components and non-CVD outcomes such as cancer,
Alzheimer’s disease, and chronic obstructive pulmonary
disease (COPD). Effect estimates from the genetic ana-
lysis were compared to those from intervention trials
where the outcomes under evaluation overlapped.
Methods
We summarise methods briefly here as they have been
previously described in detail [14].
Genetic variant selection
SNPs rs11583680 (minor allele frequency [MAF] = 0.14),
rs11591147 (MAF = 0.01), rs2479409 (MAF = 0.36) and
rs11206510 (MAF = 0.17) were selected as genetic instru-
ments at the PCSK9 locus based on the following criteria:
(1) an LDL-C association as reported by the Global Lipids
Genetics Consortium (GLGC) [15]; (2) low pairwise linkage
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disequilibrium (LD) (r2 ≤ 0.30) with other SNPs in the re-
gion (based on 1000 Genomes CEU data); and (3) the com-
bined annotation dependent depletion (CADD) score [16]
which assesses potential functionality (see Additional file 1:
Table S1).
Previously, we explored the between-SNP correla-
tions (see Additional file 2: Figure S1 of Schmidt et al.
2017 [14]), revealing an $r^2$ of 0.26 between
rs11206510 and rs11583680, confirming all other SNPs
were approximately independent (r2 ≤ 0.07). Subse-
quent adjustment for the residual LD (correlation)
structure did not impact results (see Appendix Figure
90 of Schmidt et al. 2017 [14]).
Individual participant-level and summary-level data
Participating studies (Additional file 1: Table S2) provided
analyses of individual participant-level data (IPD) based
on a common analysis script (available from AFS), submit-
ting summary estimates to the UCL analysis centre. These
data were supplemented with public domain data from
relevant genetic consortia (Additional file 1: Table S3).
Studies contributing summary estimates to genetic con-
sortia were excluded from the IPD component of the ana-
lysis to avoid duplication.
Biomarker data were collected on the major routinely
measured blood lipids (LDL-C, HDL-C, triglycerides [TG],
total cholesterol [TC]); apolipoproteins A1 [ApoA1] and B
[ApoB], and nominal lipoprotein (Lp)(a); systolic (SBP) and
diastolic (DBP) blood pressure; inflammation markers C-
reactive protein (CRP), interleukin-6 (IL-6), and fibrino-
gen; haemoglobin; glycated haemoglobin (HbA1c); liver
enzymes gamma-glutamyltransferase (GGT), alanine ami-
notransferase (ALT), aspartate transaminase (AST), and
alkaline phosphatase (ALP); serum creatinine, and cogni-
tive function (standardized to mean 0, and standard devi-
ation 1, see Additional file 1: Table S5).
We focussed on individual clinical endpoints, rather than
composites, which have been assessed in outcome trials, as
well as disease end-points commonly seen in patients likely
to be eligible for PCSK9 inhibitor treatment. Ischemic CVD
endpoints studied were myocardial infarction (MI), ische-
mic stroke, revascularization, and angina. The following
non-ischemic CVD events were considered: haemorrhagic
stroke, heart failure, and atrial fibrillation. Non-CVD out-
come data was collected on common chronic diseases:
COPD, any cancer (including those of the breast, pros-
tate, colon and lung), Alzheimer’s disease, and T2DM.
Study endpoints and biomarker were chosen based on a
combination of 1) available sample size, 2) clinical rele-
vance, and 3) evaluation in RCTs of PCSK9 inhibition, we
did not a priori hypothesize on the likelihood of PCSK9
being associated with any of the available phenotypes.
Specific cancer sites evaluated here: chronic lymphocytic
leukaemia, multiple myeloma, Hodgkin, meningioma,
glioma, melanoma, colorectal cancer, prostate cancer,
breast cancer, lung adenocarcinoma, and small-cell lung
cancer.
Finally, aggregated trial data on the effect of monoclo-
nal PCSK9 (13 alirocumab trials, and 4 evolocumab
trials) inhibitors were compared to placebo for MI, revas-
cularization, ischemic or haemorrhagic stroke, cancer, and
T2DM abstracted from the Cochrane systematic review
[6, 17], with the addition of the OUTCOMES alirocumab
trial published afterwards [18]. We compared effects on
biomarkers and clinical endpoints common to both the
genetic analysis and trials.
Statistical analyses
In all analyses, we assumed an additive allelic effect with
genotypes coded as 0, 1 and 2, corresponding to the
number of LDL-C lowering alleles; model comparison
tests did not show signs of non-additivity [14]. Continu-
ous biomarkers were analysed using linear regression
and binary endpoints using logistic regression. Study-
specific associations were pooled for each SNP using the
inverse variance weighted method for fixed effect meta-
analysis. Study-specific associations were excluded if the
SNP was not in Hardy-Weinberg equilibrium (see
Additional file 1: Table S4, based on a Holm-Bonferroni
alpha criterion), with no variants failing this test. We
estimated the effect at the PCSK9 locus by combining all
four SNPs in a gene centric score (GS) as the inverse
variance weighted effect of the 4 variants, that were sub-
sequently scaled by the inverse variance weighted effect
on LDL-C.
Trial data were assembled as per Schmidt et al. 2017
[6]. Briefly, systematic searches were performed using
the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, Web of Science
registries, Clinicaltrials.gov and the International Clinical
Trials Registry Platform databases. Data from placebo
controlled trials were extracted and combined using the
inverse variance weighted method for continuous data
and a random-intercept logistic regression model for
binary data [6].
Results are presented as mean differences (MD) or odds
ratios (OR) with 95% confidence intervals (CI). Analyses
were conducted using the statistical programme R version
3.4.1 [19]. For study specific estimates please contact AFS.
Results
Participant level data were available from up to 246,355
individuals, and were supplemented by summary effect
estimates from data repositories, resulting in a sample
size of 320,170 individuals, including 95,865 cases of MI,
16,437 stroke, 11,920 ischemic stroke, 51,623 T2DM, 54,
702 cancer, 25,630 Alzheimer’s disease and 12,412 of
COPD.
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Lipid and apolipoprotein associations
As reported previously [14], the four PCSK9 SNPs
were associated with lower LDL-C blood concentra-
tions ranging from − 0.02 mmol/L (95% CI -0.03, −
0.02) per allele for rs11583680 to − 0.34 mmol/L (95%
CI -0.36; − 0.32) for rs11591147 (See Additional file 2:
Figure S1). PCSK9 SNPs associated with a lower
LDL-C concentration were also associated with lower
concentrations of apolipoprotein B proportionate to
the LDL-C association.
Associations of the GS with the other lipids or apolipo-
proteins, scaled to a 1mmol/L lower LDL-C were
(Table 1): 0.05mmol/L (95% CI 0.02, 0.07) for HDL-C, −
0.07mmol/L (95% CI -0.12, − 0.01) for TG, − 1.06mmol/L
(95% CI -1.12, − 1.00) for TC, − 0.20 g/L (95% CI -0.25, −
0.18) for ApoB, 0.02 g/L (95% CI -0.01, 0.06) for ApoA1,
and − 4.12mg/dL (95% CI -8.62, 0.38) for Lp(a).
The associations of the PCSK9 GS with blood-based
lipid markers were directionally concordant with effects
from treatment trials of therapeutic inhibition of PCSK9
(Fig. 1).
Genetic associations with other biochemical and
physiological measures
The GS estimates with SBP and DBP were 0.03mmHg
(95% CI -0.05, 0.10) and 0.08mmHg (95% CI 0.0001, 0.15),
respectively, per 1mmol/L lower LDL-C. The PCSK9 GS
was associated with nominally lower ALP (IU/L) -0.06
(95% CI -0.09, − 0.02), but not with other liver enzymes
(Table 1).
Genetic associations with ischemic cardiovascular events
The PCSK9 GS was associated with a lower risk of
MI (OR 0.53; 95% CI 0.42; 0.68; 95,865 cases), which
was directionally consistent with results from placebo-
controlled PCSK9 inhibition trials: OR 0.90 (95% CI
0.86, 0.93), with both estimates scaled to a 1 mmol/L
lower LDL-C (Figs. 2 and 3). The genetic effect esti-
mate for ischemic stroke was OR 0.84 (95% CI 0.57,
1.22, 11,920 cases), concordant in direction to that of
the drugs trials (OR 0.85 95% CI 0.78; 0.93). Simi-
larly, the PCSK9 GS association with coronary revas-
cularization (OR 0.75 95% CI 0.44; 1.27) was
directionally consistent with the PCSK9 inhibitor tri-
als (OR 0.90; 95% CI 0.86, 0.93) (Fig. 3).
Table 1 Biomarker associations of a PCSK9 gene centric score,
effect presented as mean difference (MD) with 95% confidence
interval in brackets with the effects scaled to a 1 mmol/L
decrease in LDL-C
Biomarker Total sample size MD (95% CI)
Lipids related biomarkers
HDL-C in mmol/L 314,078 0.05 (0.02; 0.07)
TG in mmol/L 298,069 −0.07 (− 0.12; − 0.01)
TC in mmol/L 320,170 − 1.06 (− 1.12; − 1.00)
ApoA1 in g/L 55,477 0.02 (− 0.01; 0.06)
ApoB in g/L 54,643 −0.20 (− 0.25; − 0.18)
LP [a] in mg/dL 21,181 −4.12 (−8.62; 0.38)
Safety related biomarkers
SBP in mmHG 182,487 0.03 (−0.05; 0.10)
DBP in mmHG 182,497 0.08 (0.001; 0.15)
CRP in log (mg/L) 91,990 0.03 (−0.07; 0.14)
IL-6 in log (pmol/L) 22,370 −0.08 (− 0.21; 0.04)
GGT in log (IU/L) 69,488 0.03 (−0.04; 0.10)
Fibrinogen in log(g/dL) 63,288 0.02 (−0.01; 0.04)
Hemoglobin in g/L 52,109 1.16 (−0.38; 2.70)
ALT in log (IU/L) 83,223 0.03 (−0.02; 0.08)
AST in log (IU/L) 49,556 0.01 (−0.03; 0.05)
ALP in log (IU/L) 60,222 −0.06 (− 0.09; − 0.02)
Creatinine in umol/L 100,206 0.06 (−1.43; 1.55)
Nota bene, TG triglycerides, TC Total cholesterol, ApoA1 Apolipoprotein A1,
ApoB Apolipoprotein B, LPa Lipoprotein a, SBP Systolic blood pressure, DBP
Diastolic blood pressure, CRP C-reactive protein, IL-6 Interleukin-6, GGT
Gamma-glutamyltransferase, ALT Alanine transaminase, AST Aspartate
transaminase, ALP Alkaline phosphatase
Fig. 1 Lipid and lipoprotein associations of a PCSK9 gene-centric
score (GS) compared to placebo-controlled randomized trials of
therapeutic inhibition of PCSK9. Footnote: Effect estimates are
presented as mean differences, with 95% confidence interval (CI).
Trial estimates are presented as percentage change from
baseline (during 6 months of follow-up), and GS estimates scaled to
a 1mmol/L lower LDL-C (mmol/L). Results are pooled using a fixed
effect model. Trial estimates are based on the systematic review by
Schmidt et al 2017 [6, 17]
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Genetic associations with non-ischemic cardiovascular
disease
The point estimate for the GS association with hemorrhagic
stroke (Fig. 2), OR 1.29 (95% CI 0.76, 2.19), was discordant
to the estimate from PCSK9 inhibitor trials (OR 0.96 95%
CI 0.75; 1.23) (Fig. 3), although the confidence intervals
overlapped. Comparing the association of PCSK9 GS with
hemorrhagic and ischemic stroke indicated the GS had a
differential effect (p-value = 0.02). No PCSK9 GS associ-
ation was observed with atrial fibrillation (OR 0.92 95% CI
0.72; 1.18; 41,485 cases), or heart failure (OR 1.06 95% CI
0.48; 2.32; 1803 cases) (Fig. 2).
Associations with non-cardiovascular disease and related
biomarkers
The PCSK9 GS was not associated with the risk of any can-
cer (OR 0.97: 95%CI 0.81; 1.17; 54,702 cases, see Fig. 4), nor
with any of 12 specific types of cancer (Additional file 2:
Figure S2). We did not observe an association with
either Alzheimer’s disease or cognitive performance: for
Alzheimer’s the OR was 0.91 (95% CI 0.55, 1.51) and
for cognition (per standard deviation) -0.03 (95% CI
-0.22, 0.16). As reported before [14] the GS was associ-
ated with T2DM (OR 1.29 95% CI 1.11; 1.50) (Fig. 4),
higher body weight (1.03 kg, 95% CI 0.24, 1.82), waist to
hip ratio 0.006 (95% CI 0.003, 0.011) and fasting glucose
0.09mmol/L (95% CI 0.02, 0.15). The OR for COPD was
0.89 (95% CI 0.67, 1.18).
Discussion
The genetic findings presented here show that vari-
ation in PCSK9 is associated with lower circulating
LDL-C and apoB concentrations, lower risk of MI
and, with lesser confidence, the risk of ischemic
stroke and coronary revascularization. These effects
are consistent in direction to effects observed in
PCSK9 inhibitor trial’s [20].
A recent systematic review of trial data [21] indicated
PCSK9 inhibition was associated with increased fasting
glucose (0.17 as standardized mean difference [SMD]
95% CI 0.14; 0.19) and glycosylated haemoglobin (0.10
SMD 95% CI 0.07, 0.12, 21), although these associa-
tions were dependent on the inclusion of the terminated
bococizumab trials. Recently we, and others, showed
natural genetic variation PCSK9 was associated with ele-
vated fasting glucose and T2DM [14, 22, 23] and that
variation at other LDL-C-associated loci also influence
risk of T2DM [24, 25]. However, the FOURIER and
ODYSSEY OUTCOMES trials, the largest treatment trials
of PCSK9 inhibitors to date, did not find an association
with risk of incident T2DM, at a median follow up of 2.2
and 2.8 years respectively. It is possible this reflects a
genuine discordance between the findings from trials and
genetic analyses. Alternatively, the exposure durations in
the two largest trials may simply have been too short for
subjects to develop T2DM. The risk increasing effect of
statins on T2DM was only apparent after conducting a
Fig. 2 Associations of a PCSK9 gene-centric score with ischemic and
non-ischemic cardiovascular endpoints. Footnote: Effect estimates
are presented as odds ratios (OR), with 95% confidence interval (CI)
scaled to a 1 mmol/L lower LDL-C (mmol/L). Results are pooled
using a fixed effect model. The size of the squares are proportional
to the inverse of the variance Fig. 3 Clinical endpoint associations of the PCSK9 gene-centric score
(GS) as compared to placebo-controlled randomized trials of
therapeutic inhibition of PCSK9. Footnote: Effect estimates are
presented as odds ratios (OR), with 95% confidence interval (CI), for
the GS scaled to a 1 mmol/L lower LDL-C (mmol/L). Results are
pooled using a fixed effect model. Trial estimates are based on the
systematic review by Schmidt et al 2017 [6], with the estimates on
ischemic stroke and revascularization solely based on the FOURIER
and ODYSSEY OUTCOMES trials
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meta-analysis of 13 statin trials in which 4278 T2DM
cases were observed during an average follow-up of 4
years [26].
In general, inconsistencies between associations of
variants in a gene encoding a drug target and the ef-
fects of the corresponding treatment are possible on a
number of theoretical grounds. The effects of genetic
variation (present from conception) may be mitigated
by developmental adaptation or environmental changes. A
lack of association of a genetic variant with an outcome
therefore does not preclude an effect of a treatment
administered in later life, when adaptive responses
may no longer be available, or in the presence of a
particular environment [27]. We selected a subset of
all genetic variants at PCSK9 that capture information
on many others and which have some annotated func-
tion. However, other approaches to more fully capture
the entire gene-centric effect are worthy of future in-
vestigation [28].
The association of PCSK9 variants with LDL-C and
MI has been reported before [5], and was a motivating
factor for the development of PCSK9 inhibiting drugs.
Lotta and colleagues [22] reported a similar OR for MI
of 0.60 (95% CI 0.48, 0.75) per 1 mmol/L decrease in
LDL-C using the PCSK9 rs11591147 SNP. Using a seven
SNP PCSK9 GS, Ference et al. reported a MI OR of 0.44
(95% CI 0.31, 0.64) per 1 mmol/L decrease in LDL-C
[23]. These scaled genetic effects are larger than the
treatment effect observed in trials which others have
noted previously [29], and ascribed to the lifelong effect
of genetic variation versus the short-term effect of drug
treatment in later life.
The available trial data showed PCSK9 inhibitors had
a similar effect on MI (OR 0.90, 95% CI 0.86; 0.93) and
ischemic stroke (OR 0.85 95% CI 0.78; 0.93). By contrast,
the genetic analysis indicated a directionally concordant,
but larger effect on MI (OR 0.53; 95% CI 0.42; 0.68) than
ischemic stroke, (OR 0.84 95% CI 0.57; 1.22). The gen-
etic analysis was, however, based on only 11,920 stroke
cases, about one-fifth of the number of cases available
for the genetic analysis of MI and as such confidence
interval overlapped. We did observe a differential associ-
ation between PCKS9 SNPs and ischemic and
hemorrhagic stroke (interaction p-value = 0.02). Findings
from statin trials previously suggested LDL-C lowering
through inhibition of HMG-coA reductase is associated
with a reduced risk of ischemic but potentially increased
risk of hemorrhagic stroke [30–32]. Our findings suggest
that a different effect on ischemic and hemorrhagic
stroke subtypes may be eventually identified for PCSK9
inhibitors.
Despite previous concerns about a potential effect of
this class of drugs on cognition [33], the genetic analysis
did not reveal a significant association of the PCSK9 var-
iants with cognitive function or Alzheimer’s disease, nor
with COPD or cancer, though this does not preclude an
effect on such outcomes from drug treatment given in
later life. While we explored the associations with any
cancer (54,702 events) as well as individual cancer sites
(Additional file 2: Figure S2), we did not have data on
some clinically relevant cancer types such as endometrial
cancer.
This neutral effect on cognition has been recently re-
ported by the EBBINGHAUS study, nested within the
FOURIER trial, which reported a non-significant PCSK9
inhibitor effect on multiple measures of cognition con-
firming (using a non-inferiority design) an absence of
effect [33]; it should be noted that similar to the FOU-
RIER, the EBBINGHAUS follow-up time was limited.
The absence of an effect on cognition during PCSK9 in-
hibitor treatment was also observed in the ODYSSEY
OUTCOMES trial, which had a median follow-up [7] of
2.8 years.
Drugs (even apparently specific monoclonal anti-
bodies) can exert actions on more than one protein if
such targets belong to a family of structurally similar
proteins. PCSK9, for example, is one of nine related
proprotein convertases [34]. Such ‘off-target’ actions,
whether beneficial or deleterious, would not be shared
by variants in the gene encoding the target of interest. In
addition, monoclonal antibodies prevent interaction be-
tween circulating PCSK9 and LDL-receptor and should
not, in theory, influence any intracellular action of the
protein [35].
Genetic association studies of the type conducted here
tend to examine the risk of a first clinical event, whereas
Fig. 4 Associations of a PCSK9 gene-centric score (GS) with non-
cardiovascular events. Footnote: Effect estimates are presented as
odds ratios (OR), with 95% confidence interval (CI) scaled to a 1
mmol/L lower LDL-C (mmol/L). Results are pooled using a fixed
effect model. The size of the squares are proportional to the inverse of
the variance. Note, that all GS estimates are based on 4 SNPs, except
for the Alzheimer’s disease estimate which excluded the SNP
rs11591147 due to lack of data
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clinical trials such as ODYSSEY OUTCOMES focus on
patients with established disease, where mechanisms
may be modified. Proteins influencing the risk of a first
event may also influence the risk of subsequent events,
as observed in the case of the target of statin drugs that
are effective in both primary and secondary prevention
[1]. For this and other reasons [36–38], examination of
the effects of PCSK9 variants on the risk of subsequent
CHD events in patients with established coronary ath-
erosclerosis is the subject of a separate analysis led by
the GENIUS-CHD consortium [38].
Conclusions
PCSK9 SNPs associated with lower LDL-C predict a
substantial reduction in the risk of MI and concordant
associations with a reduction in risk of ischemic stroke,
but with a modestly increased risk of T2DM. In this pre-
liminary analysis we did not observe associations with
other non-cardiovascular safety outcomes such as can-
cer, COPD, Alzheimer’s disease or atrial fibrillation.
Additional files
Additional file 1: Supplemental tables. (XLSX 62 kb)
Additional file 2: Supplemental figures and study acknowledgments.
(PDF 154 kb)
Abbreviations
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase;
ApoA1: Apolipoproteins A1; ApoB: Apolipoproteins B; AST: Aspartate
transaminase; CADD: Combined annotation dependent depletion;
CHD: Coronary heart disease; CI: Confidence interval; COPD: Chronic
obstructive pulmonary disease; CRP: C-reactive protein; CVD: Cardiovascular
disease; DBP: Diastolic blood pressure; GGT: Gamma-glutamyltransferase;
GLGC: Global lipids genetics Consortium; GS: Gene-centric score;
HbA1c: Glycated haemoglobin; IL-6: Interluekin-6; IPD: Individual participant-
level data; LD: Linkage disequilibrium; LDL-C: Low density lipoprotein-
cholesterol; LPa: Lipoprotein a; mAbs: Monoclonal antibodies; MAF: Minor
allele frequency; MD: Mean difference; MI: Myocardial infarction; OR: Odds
ratio; SBP: Systolic blood pressure; SMD: Standardized mean difference;
T2DM: Type 2 diabetes mellitus; TC: Total cholesterol; TG: Triglycerides
Acknowledgements
Not applicable
Authors’ contributions
AFS, DIS, MVH, RSP, FWA, JPC, BJK, ADH, DP, NS contributed to the idea and
design of the study. AFS, DIS, MVH, designed the analysis scripts shared with
individual centres. AFS performed the meta-analysis and had access to all
the data. The authors jointly drafted the manuscript, and contributed to
subsequent critical revisions. All authors have approved the submitted
manuscript, and take responsibility for the integrity and the accuracy of the
data and presented results.
Funding
Dr. Schmidt is supported by BHF grant PG/18/5033837. Dr. Preiss is supported
by a University of Oxford BHF Centre of Research Excellence Senior Transition
Fellowship (RE/13/1/30181). This research has been funded by the British Heart
Foundation (SP/13/6/30554, RG/10/12/28456), and the UCL BHF Research
Accelerator grant (AA/18/6/24223). The work was also supported by UCL
Hospitals NIHR Biomedical Research Centre and by the Rosetrees and
Stoneygate Trusts. This research has been conducted using the UK Biobank
Resource under Application Number 12113. The authors are grateful to UK
Biobank participants. UK Biobank was established by the Wellcome Trust
medical charity, Medical Research Council, Department of Health, Scottish
Government, and the Northwest Regional Development Agency. It has also had
funding from the Welsh Assembly Government and the British Heart
Foundation. We thank the International Genomics of Alzheimer’s Project (IGAP)
for providing summary results data for these analyses. The investigators within
IGAP contributed to the design and implementation of IGAP and/or provided
data but did not participate in analysis or writing of this report. IGAP was made
possible by the generous participation of the control subjects, the patients, and
their families. The i–Select chips was funded by the French National Foundation
on Alzheimer’s disease and related disorders. EADI was supported by the LABEX
(laboratory of excellence program investment for the future) DISTALZ grant,
Inserm, Institut Pasteur de Lille, Université de Lille 2 and the Lille University
Hospital. GERAD was supported by the Medical Research Council (Grant n°
503480), Alzheimer’s Research UK (Grant n° 503176), the Wellcome Trust (Grant
n° 082604/2/07/Z) and German Federal Ministry of Education and Research
(BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711,
01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193
and the NIA AG081220 and AGES contract N01–AG–12100, the NHLBI grant
R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center
and Erasmus University. ADGC was supported by the NIH/NIA grants: U01
AG032984, U24 AG021886, U01 AG016976, and the Alzheimer’s Association
grant ADGC–10–196728. We acknowledge the International Consortium for
Blood Pressure Genome-Wide Association Studies (Nature. 2011 Sep
11;478(7367):103–9, Nat Genet. 2011 Sep 11;43(10):1005–11). This work was sup-
ported in part by Deutsche Forschungsgemeinschaft (DFG Az Si 552/2), the Uni-
versity of Bonn (BONFOR O-126.0030), and Deutsche Krebshilfe (70/2385/WI2,
70/3163/WI3; PI Prof. J Schramm, Dept. Bloodwise provided funding for the
study (LRF05001, LRF06002 and LRF13044) with additional support from Cancer
Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the
Arbib Fund. Wellcome Trust [064947/Z/01/Z and 081081/Z/06/Z]; from the Na-
tional Institute on Aging [1R01 AG23522–01]; and the MacArthur Foundation
“MacArthur Initiative on Social Upheaval and Health” [71208]. The British
Women’s Heart and Health Study is supported by the British Heart Foundation
(PG/13/66/30442). Data on mortality and cancer events were routinely provided
from NHS Digital to the BWHHS under data sharing agreement MR104a-
Regional Heart Study (Female Cohort). British Women’s Heart and Health Study
data are available to bona fide researchers for research purposes. Please refer to
the BWHHS data sharing policy at www.ucl.ac.uk/british-womens-heart-health-
study . Hartmut Goldschmidt acknowledges support from the Deutsche
Krebshilfe, the Dietmar Hopp Foundation and the German Ministry of Education
and Science (BMBF: CLIOMMICS (01ZX1309), Deutsche Krebshilfe, the Dietmar
Hopp Foundation and the German Ministry of Education and Science (BMBF:
CLIOMMICS (01ZX1309). The Novo Nordisk Foundation Center for Basic
Metabolic Research is an independent Research Center at the University of
Copenhagen partially funded by an unrestricted donation from the Novo
Nordisk Foundation (www.metabol.ku.dk). This study was supported by the Farr
Institute of Health Informatics Research, funded by The Medical Research
Council (MR/K006584/1), in partnership with Arthritis Research UK, the British
Heart Foundation, Cancer Research UK, the Economic and Social Research
Council, the Engineering and Physical Sciences Research Council, the National
Institute of Health Research, the National Institute for Social Care and Health
Research (Welsh Assembly Government), the Chief Scientist Office (Scottish
Government Health Directorates) and the Wellcome Trust. Christina M Lill is
supported by the Possehl foundation, Renate Maaß Foundation. Mika Kivimaki
was supported by MRC (K013351 and R024227) and a Helsinki Institute of Life
Science fellowship. Michael Holmes is supported by a British Heart Foundation
Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National
Institute for Health Research Oxford Biomedical Research Centre. Dr. Patel is
supported by a BHF clinical intermediate fellowship (FS/14/76/30933).
The funding sources had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; preparation,
review, or approval of the manuscript; and decision to submit the
manuscript for publication.
Lifelines Cohort authors see Additional file 2.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Schmidt et al. BMC Cardiovascular Disorders          (2019) 19:240 Page 7 of 10
Ethics approval and consent to participate
Local ethics committees for studies contributing data to these analyses
granted approval for the work.
Consent for publication
Not applicable
Competing interests
Dr. Holmes has collaborated with Boehringer Ingelheim in research, and in
accordance with the policy of the The Clinical Trial Service Unit and
Epidemiological Studies Unit (University of Oxford), did not accept any
personal payment. David Preiss consulted for Amgen on a single occasion
but, in accordance with the policy of the Clinical Trial Service Unit (University
of Oxford), did not accept any personal payment. He is an investigator on a
clinical trial of the PCSK9 synthesis inhibitor, inclisiran, funded by a grant to
the University of Oxford by the Medicines Company, but he receives no
personal fees from this grant. Daniel I Swerdlow is an employee of
BenevolentAI Ltd. Aroon Hingorani and Harry Hemingway are National
Institute for Health Research Senior Investigators. Naveed Sattar consulted for
Amgen and Sanofi related to PCSK9 inhibitors; and was an investigator on
clinical trials of PCSK9 inhibition funded by Amgen. Naveed Sattar has also
consulted for Boehringer Ingelheim, Janssen, Eli-Lilly and NovoNordisk. Daniel
Swerdlow has consulted to Pfizer for work unrelated to this paper. Folkert W.
Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre.
Dr. Patel has received honoraria and speaker fees from Sanofi, Amgen and
Bayer. Kees Hovingh or his institution (AMC) received honoraria for consult-
ancy, ad boards, and/or conduct of clinical trials from: AMGEN, Aegerion, Pfi-
zer, Astra Zeneca, Sanofi, Regeneron, KOWA, Ionis pharmaceuticals and
Cerenis. Bertrand Cariou has received research funding from Pfizer and
Sanofi, received honoraria from AstraZeneca, Pierre Fabre, Janssen, Eli-Lilly,
MSD Merck & Co., Novo-Nordisk, Sanofi, and Takeda, and has acted as a con-
sultant/advisory panel member for Amgen, Eli Lilly, Novo-Nordisk, Sanofi, and
Regeneron. Andrzej Pająk acted as a consultant/advisory pannel member for
Amgen. Erik Ingelsson is a scientific advisor for Precision Wellness and Olink
Proteomics for work unrelated to this paper. JCH is a scientific advisor to a
clinical trial of PCSK9 inhibition. AE Honoraria: Takeda, BMS, Amgen; Consult-
ing: Takeda, BMS, Amgen. SEH acknowledges BHF funding (PG008/08) and
support from the UCL BRC. All other authors declare no competing interests.
Author details
1Institute of Cardiovascular Science, University College London, 222 Euston
Road, London NW1 2DA, UK. 2Department of Cardiology, Division Heart &
Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, the
Netherlands. 3UCL’s BHF Research Accelerator Centre, London, UK. 4Medical
Research Council Population Health Research Unit, Clinical Trial Service Unit
& Epidemiological Studies Unit (CTSU), Nuffield Department of Population
Health, University of Oxford, Oxford, UK. 5Department of Medicine, Imperial
College London, London, UK. 6Health Data Research UK, University College
London, 222 Euston Road, London NW1 2DA, UK. 7Institute of Health
Informatics, University College London, 222 Euston Road, London NW1 2DA,
UK. 8The Alan Turing Institute, British Library, 96 Euston Rd, London NW1
2DB, UK. 9University College London, Farr Institute of Health Informatics,
London, UK. 10Clinical Trial Service Unit & Epidemiological Studies Unit
(CTSU), Nuffield Department of Population Health, University of Oxford,
Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF,
UK. 11Postgraduate Program in Epidemiology, Federal University of Pelotas,
Pelotas, Brazil. 12Centre for Population Health Research, Sansom Institute for
Health Research, University of South Australia, Adelaide, Australia.
13Population, Policy and Practice, UCL GOS Institute of Child Health, London,
UK. 14South Australian Health and Medical Research Institute, Adelaide,
Australia. 15Durrer Center for Cardiovascular Research, Netherlands Heart
Institute, Utrecht, The Netherlands. 16Department of Clinical Epidemiology,
Biostatistics And Bioinformatics, Academic Medical Center Amsterdam,
Amsterdam, the Netherlands. 17Department of vascular medicine, Academic
Medical Center Amsterdam, Amsterdam, the Netherlands. 18Charité –
Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
Humboldt-Universität zu Berlin, and Berlin Institute of Health, Lipid Clinic at
the Interdisciplinary Metabolism Center, Berlin, Germany. 19Charité -
Universitätsmedizin Berlin, BCRT - Berlin Institute of Health Center for
Regenerative Therapies, Berlin, Germany. 20Institute of Nutritional Science,
University of Potsdam, 14558 Nuthetal, Germany. 21Geriatrics Research Group,
Charité - Universitätsmedizin Berlin, 13347 Berlin, Germany. 22Department of
Nutrition and Gerontology, German Institute of Human Nutrition
Potsdam-Rehbruecke, 14558 Nuthetal, Germany. 23E.CA Economics GmbH,
Berlin, Germany. 24Lübeck Interdisciplinary Platform for Genome Analytics
(LIGA), Institutes of Neurogenetics & Cardiogenetics, University of Lübeck,
Lübeck, Germany. 25Center for Lifespan Changes in Brain and Cognition (LCBC),
Dept. Psychology, University of Oslo, Oslo, Norway. 26Genetic and Molecular
Epidemiology Group, Lübeck Interdisciplinary Platform for Genome Analytics
(LIGA), Institutes of Neurogenetics & Cardiogenetics, University of Lübeck,
Lübeck, Germany. 27Institute of Human Genetics, Lübeck, Germany. 28Ageing
Epidemiology Research Unit, School of Public Health, Imperial College, London,
UK. 29Institute of Genetic Epidemiology, Department of Genetics and
Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
30Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
31Department of Neurology, Inselspital, University Hospital Bern, University of
Bern, Bern, Switzerland. 32Bradford Institute for Health Research, Bradford Royal
Infirmary, Bradford, UK. 33Department Primary Care & Population Health,
University College London, London, UK. 34Population Health Research Institute,
St George’s, University of London, London, UK. 35Population Health Sciences,
University of Bristol, Bristol, UK. 36Centre for Population Health Sciences, The
Usher Institute, University of Edinburgh, Edinburgh, UK. 37Department of
Epidemiology and Public Health, UCL Institute of Epidemiology and Health
Care, University College London, London, UK. 38Department of Medicine,
Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland.
39Department of Vascular Surgery, Imperial College, London, United Kingdom.
40Department of Surgery, Nicosia Medical School, University of Nicosia, Nicosia,
Cyprus. 41Cyprus International Institute for Environmental and Public Health,
Cyprus University of Technology, Limassol, Cyprus. 42Julius Center for Health
Sciences and Primary Care, University Medical Center Utrecht, Utrecht
University, Utrecht, the Netherlands. 43Italian Institute for Genomic Medicine
(IIGM), Turin, Italy. 44Department of Medical Sciences, University of Turin, Turin,
Italy. 45Unit of Cancer Epidemiology, Città della Salute e della Scienza
University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy. 46MRC
Epidemiology Unit, Institute of Metabolic Science, University of Cambridge
School of Clinical Medicine, Cambridge Biomedical Campus, Addenbrooke’s
Hospital, Cambridge, UK. 47Novosibirsk State Medical University, Novosibirsk,
Russian Federation. 48Institute of Internal and Preventive Medicine, Siberian
Branch of the Russian Academy of Medical Sciences, Novosibirsk, Russian
Federation. 49Department of Epidemiology and Population Studies, Faculty of
Health Sciences, Jagiellonian University Medical College, Kraków, Poland.
50National Institute of Public Health, Prague, Czech Republic. 51Lithuanian
University of Health Sciences, Kaunas, Lithuania. 52Novo Nordisk Foundation
Center for Basic Metabolic Research, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark. 53Department of Clinical
Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark. 54Center for Clinical Research and Prevention,
Bispebjerg and Frederiksberg Hospital, Copenhagen, The Capital Region of
Denmark, Denmark. 55Centre for Cardiovascular Genetics, Department of
Medicine, University College London, London, UK. 56Center for Human
Genetics, Marshfield Clinic Research Institute, Marshfield, USA. 57Children’s
Hospital of Philadelphia, Philadelphia, USA. 58University of Minnesota,
Minneapolis, USA. 59Geisinger, Danville, USA. 60Kaiser Permanente Washington
Health Research Institute, Seattle, WA, USA. 61Department of Biomedical
Informatics and Medical Education University of Washington Seattle, Seattle,
WA, USA. 62Mayo Clinic, Rochester, USA. 63Department of Medicine,
Department of Pharmacology, Department of Biomedical Informatics,
Vanderbilt University School of Medicine, Nashville, TN, USA. 64Vanderbilt
University, Nashville, USA. 65WHI, Seattle, USA. 66University of Newcastle,
Newcastle, NSW, Australia. 67Public Health Program, Hunter Medical Research
Institute, Newcastle, NSW, Australia. 68Hunter New England Local Health District,
Newcastle, NSW, Australia. 69Population Health Research Institute, Hamilton,
Ontario, Canada. 70Department of Genetics, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands. 71Department of
Cardiology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands. 72Department of Epidemiology, University of
Groningen, University Medical Center Groningen, Groningen, Netherlands.
73Department of Clinical Epidemiology, Leiden University Medical Center,
Leiden, The Netherlands. 74Department of Medical Sciences, Molecular
Epidemiology, Uppsala University, Uppsala, Sweden. 75Department of Medicine,
Division of Cardiovascular Medicine, Stanford University School of Medicine,
Stanford, CA 94305, USA. 76Department of Medical Sciences, Molecular
Schmidt et al. BMC Cardiovascular Disorders          (2019) 19:240 Page 8 of 10
Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala,
Sweden. 77Department of Epidemiology, Erasmus University Medical Center,
Rotterdam, the Netherlands. 78Department of Epidemiology and Biostatistics,
Imperial College London, London, UK. 79Institute for Community Medicine,
University Medicine Greifswald, Greifswald, Germany. 80DZHK (German Centre
for Cardiovascular Research), partner site Greifswald, Greifswald, Germany.
81Chair of Epidemiology, Ludwig-Maximilians-Universität München, UNIKA-T
Augsburg, Augsburg, Germany. 82Department of Internal Medicine B, University
Medicine Greifswald, Greifswald, Germany. 83Department of Internal Medicine A,
University Medicine Greifswald, Greifswald, Germany. 84Interfaculty Institute of
Genetics and Functional Genomics, University Medicine Greifswald, Greifswald,
Germany. 85Institute of Health and Wellbeing, University of Glasgow, Glasgow
G12 8RZ, Scotland, UK. 86Department of Non-Communicable Disease
Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
87The Department of Medical Research, Bærum Hospital, Vestre Viken Hospital
Trust, Gjettum, Norway. 88Division of Pharmacoepidemiology and Clinical
Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Faculty of Science,
Utrecht University, Utrecht, The Netherlands. 89Department of Respiratory
Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the
Netherlands. 90Robertson Centre for Biostatistics, University of Glasgow,
Glasgow, UK. 91Institute of Genetics and Molecular Medicine, University of
Edinburgh, Edinburgh, UK. 92Institute of Cardiovascular and Medical Sciences,
University of Glasgow, Glasgow G12 8TA, UK. 93CNRS UMR 8199, European
Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, University of Lille,
59000 Lille, France. 94Department of Genomics of Common Disease, Imperial
College London, W12 0NN London, United Kingdom. 95INSERM, U-1138, Centre
de Recherche des Cordeliers, Paris, France. 96UFR de Médecine, Université Paris
Diderot, Sorbonne Paris Cité, Paris, France. 97Départment de Diabétologie,
Endocrinologie et Nutrition, Assistance Publique Hôpitaux de Paris, Hôpital
Bicha, Paris, France. 98l’institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU
Nantes, Nantes, France. 99Institute for Social and Economic Research, University
of Essex, Essex, UK. 100Wellcome Trust Centre for Human Genetics, University of
Oxford, Oxford, England. 101Boston University School of Medicine, Boston, MA,
USA. 102Harvard Medical School Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital, Boston, USA. 103UWash, Seattle, USA. 104Penn
State, State College, USA. 105University of Colorado Denver, Denver, USA.
106Division of Genetics and Epidemiology, The Institute of Cancer Research,
London, UK. 107Div. Molecular Genetic Epidemiology German Cancer Research
Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. 108Deutsches
Krebsforschungszentrum, Heidelberg, Germany. 109The Institut du Cerveau et de
la Moelle épinière – ICM, Paris, France. 110Sorbonne Universités, UPMC
Université Paris 06, UMR S 1127, F-75013 Paris, France. 111Department of
Neurosurgery, Bethel Clinic, Kantensiek 11, 33617 Bielefeld, Germany. 112Division
of Hematology-Oncology, Department of Pediatrics, Dan L. Duncan Cancer
Center, Baylor College of Medicine, Houston, Texas 77030, USA. 113Northern
Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
114Myeloma Institute for Research and Therapy, University of Arkansas for
Medical Sciences, Little Rock, USA. 115Department of Hematology, Erasmus MC
Cancer Institute, 3075 EA Rotterdam, the Netherlands. 116Hematology and
Transfusion Medicine, Department of Laboratory Medicine, BMC B13, SE-221 84
Lund, Sweden. 117University Clinic Heidelberg, Internal Medicine V and National
Center for Tumor Diseases (NCT), Heidelberg, Germany. 118Department of
Internal Medicine, University Hospital of Cologne, Cologne, Germany.
119Hematology Clinic, Skåne University Hospital, Skåne, Sweden. 120Wallenberg
Center for Molecular Medicine, Lund University, Lund, Sweden. 121The National
Institute for Health Research University College London Hospitals Biomedical
Research Centre, University College London, 222 Euston Road, London NW1
2DA, UK. 122Health Data Research UK and Institute of Health Informatics,
University College London, London, United Kingdom. 123The Barts Heart Centre,
St Bartholomew’s Hospital, London, UK. 124UPenn, Philadelphia, USA.
125Massachusetts Veterans Epidemiology and Research Information Center
(MAVERIC) Veterans Affairs Boston Healthcare System, Boston, USA.
Received: 12 April 2019 Accepted: 19 August 2019
References
1. Collaborators CTT (CTT). Efficacy and safety of cholesterol-lowering
treatment: Prospective meta-analysis of data from 90 056 participants in 14
randomised trials of statins. Lancet. 2005;366:1267–78.
2. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.
Ezetimibe sed to statin therapy after acute coronary syndromes. N Engl J
Med. 2015;372(25):2387–97.
3. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park J-G, Murphy SA, et al.
Prevention of stroke with the addition of ezetimibe to statin therapy in
patients with acute coronary syndrome in IMPROVE-IT. Circulation. 2017.
https://doi.org/10.1161/CIRCULATIONAHA.117.029095.
4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in
PCSK9, low LDL, and protection against coronary heart disease. N Engl J
Med. 2006;354:1264–72.
5. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A.
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of
ischemic heart disease: 3 independent studies and meta-analyses. J Am
Coll Cardiol. 2010;55:2833–42.
6. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani A, Casas JP.
PCSK9 monoclonal antibodies for the primary and secondary prevention of
cardiovascular disease. Cochrane Database Syst Rev. 2015;(6):CD011748.
https://doi.org/10.1002/14651858.CD011748.
7. Schwartz GG, Steg, Gabriel P, Szarek M, Bhatt DL, Bittner VA, Diaz R,
Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps
G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ,
Tamby JF, Tricoci P, White HD, Zeiher AM. Alirocumab and Cardiovascular
Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097-
107. https://doi.org/10.1056/NEJMoa1801174.
8. Hingorani A, Humphries S. Nature’s randomised trials. Lancet. 2005;
366(9501):1906–8.
9. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah
T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and
bodyweight: Evidence from genetic analysis and randomised trials. Lancet.
2015;385:351–61.
10. Swerdlow DI, Hingorani AD, Casas JP, Consortium IMR. The interleukin-6
receptor as a target for prevention of coronary heart disease: a mendelian
randomisation analysis. Lancet. 2012;379(9822):1214–24.
11. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al.
Association between C reactive protein and coronary heart disease:
mendelian randomisation analysis based on individual participant data. BMJ.
2011;342:d548.
12. Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, et al.
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and
coronary heart disease risk in 10 494 cases and 15 624 controls of european
ancestry. Circulation. 2010;121(21):2284–93.
13. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al.
Separating the mechanism-based and off-target actions of cholesteryl ester
transfer protein inhibitors with CETP gene polymorphisms. Circulation. 2010;
121:52–62.
14. Schmidt AF, Swerdlow DDI, Holmes MMV, Patel RS, Fairhurst-Hunter Z, Lyall
DM, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian
randomisation study. Lancet Diabetes Endocrinol. 2016;0(2):735–42.
15. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al.
Newly identified loci that influence lipid concentrations and risk of coronary
artery disease. Nat Genet. 2008;40:161–9.
16. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general
framework for estimating the relative pathogenicity of human genetic
variants. Nat Genet. 2014;46:310–5.
17. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani A, Casas JP.
PCSK9 monoclonal antibodies for the primary and secondary prevention of
cardiovascular disease. Cochrane Database Syst Rev. 2015;(6):CD011748.
https://doi.org/10.1002/14651858.CD011748.
18. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Alirocumab for the treatment
of hypercholesterolemia. Expert Opin Biol Ther. 2017;17:633–43.
19. R Core Team. R: A language and environment for statistical computing.
Vienna: R Foundation for Statistical Computing; 2017.
20. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, et al.
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results
from 2 randomized, double-blind, placebo-controlled, ascending-dose
phase 1 studies in healthy volunteers and hypercholesterolemic subjects on
statins. J Am Coll Cardiol. 2012;60(19):1888–98.
21. de Carvalho LSF, Campos AM, Sposito AC. Proprotein convertase Subtilisin/
Kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a
systematic review and meta-analysis with over 96,000 patient-years.
Diabetes Care. 2017.
Schmidt et al. BMC Cardiovascular Disorders          (2019) 19:240 Page 9 of 10
22. Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al.
Association between low-density lipoprotein cholesterol–lowering genetic
variants and risk of type 2 diabetes. JAMA. 2016;316(13):1383.
23. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR,
et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and
diabetes. N Engl J Med. 2016;375(22):2144–53.
24. Fall T, Xie W, Poon W, Yaghootkar H, Magi R, Knowles JW, et al. Using
genetic variants to assess the relationship between circulating lipids and
type 2 diabetes. Diabetes. 2015;64(7):2676–84.
25. White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs
FW, et al. Association of Lipid Fractions with Risks for coronary artery
disease and diabetes. JAMA Cardiol. 2016;366(6):1108–18.
26. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al.
Statins and risk of incident diabetes: a collaborative meta-analysis of
randomised statin trials. Lancet. 2010;375:735–42.
27. Smith GD, Ebrahim S. “Mendelian randomization”: can genetic epidemiology
contribute to understanding environmental determinants of disease? Int J
Epidemiol. 2003;32(1):1–22.
28. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian
randomization with fine-mapped genetic data: choosing from large
numbers of correlated instrumental variables. Genet Epidemiol. 2017;
41(8):714–25.
29. Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian
randomisation to assess potential benefit of clinical intervention. BMJ. 2012;
345(nov06 1):e7325.
30. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering
with simvastatin on stroke and other major vascular events in 20 536
people with cerebrovascular disease or other high-risk conditions. Lancet.
2004;363(9411):757–67.
31. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M,
Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic
attack. N Engl J Med. 2006;355(6):549–59.
32. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al.
Interpretation of the evidence for the effi cacy and safety of statin therapy.
Lancet. 2016;388(10059):2532–61.
33. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al.
Cognitive function in a randomized trial of Evolocumab. N Engl J Med.
2017;377(7):633–43.
34. Zhang L, Song K, Zhu M, Shi J, Zhang H, Xu L, et al. Proprotein convertase
subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and
ischemic stroke. Int J Neurosci. 2016;126(8):675–80.
35. Cariou B, Si-Tayeb K, Le May C. Role of PCSK9 beyond liver involvement.
Curr Opin Lipidol. 2015;26(3):155–61.
36. Hu Y-JYJ, Schmidt AFAF, Dudbridge F, Holmes MVMV, Brophy JM, Tragante
V, et al. Impact of selection Bias on estimation of subsequent event risk. Circ
Cardiovasc Genet. 2017;10(5):e001616.
37. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, et al.
Relations between lipoprotein(a) concentrations, LPA genetic variants, and
the risk of mortality in patients with established coronary heart disease: a
molecular and genetic association study. Lancet Diabetes Endocrinol. 2017;
5(7):534–43.
38. Patel RS, Asselbergs FW. The GENIUS-CHD consortium. Eur Heart J. 2015;
36(40):2674–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Schmidt et al. BMC Cardiovascular Disorders          (2019) 19:240 Page 10 of 10
